J&J's vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month.
Johnson & Johnson's one-shot COVID
appeared safe and effective in trials, US Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.
The FDA's panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA did so when authorizing the Pfizer
Inc and Moderna Inc vaccines
was 66% effective in preventing COVID
-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month.
Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine
was 85% effective overall in stopping severe cases of the disease.
was effective in reducing the risk of COVID
-19 and preventing PCR-test confirmed COVID
-19 at least 14 days after vaccination, the FDA said in its briefing documents.
recipients had severe side effects in the trial, but the FDA said that its analysis did not raise any specific safety concerns that would preclude issuance of an emergency use authorization.
J&J had not previously released details of its clinical trial data beyond efficacy rates.